Meeting
2014 Gastrointestinal Cancers Symposium
Chemoradiation (CRT) followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant CRT and surgery for locally advanced rectal cancer: Results of the Spanish GCR-3 randomized phase II trial after a median follow-up of 5 years.
Authors
Carlos Fernandez-Martos
Medical Oncology Department, Fundacion Instituto Valenciano De Oncologia, Valencia, Spain
Carlos Fernandez-Martos , Carles Pericay , Jorge Aparicio , Maria Jose Safont , Antonia Salud , Bartomeu Massuti , Vicente Alonso , Ruth Vera , Pilar Escudero , Marta Martin-Richard , Carlos Bosch , Juan Maurel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 383)
DOI
10.1200/jco.2014.32.3_suppl.383
Abstract #
383
Poster Bd #
A2
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A randomized phase II trial of consolidation chemotherapy after preoperative chemoradiation (preop CRT) versus CRT alone for locally advanced rectal cancer (LARC).
First Author: Sun Young Kim
Poster
2021 Gastrointestinal Cancers Symposium
Short-course radiotherapy and subsequent CAPOX plus camrelizumab followed by delayed surgery for locally advanced rectal cancer: Short-term results of a phase II trial.
First Author: Zhenyu Lin
Poster
2017 ASCO Annual Meeting
Comparison of two different neoadjuvant chemoradiatiotherapy regimens for locally advanced rectal cancer: Results of a phase II, multicenter, randomized trial.
First Author: Ji Zhu
Poster
2023 ASCO Annual Meeting
Total neoadjuvant treatment without surgery for locally advanced rectal cancer: Prospective study to assess tumor response, circulating genetic, and epigenetic biomarkers, and stromal transcriptome to interpret clinical outcome (NO-CUT trial).
First Author: Salvatore Siena